Nisa Investment Advisors LLC Has $103,000 Holdings in AstraZeneca PLC (NASDAQ:AZN)

Nisa Investment Advisors LLC lifted its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 115.4% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,400 shares of the company’s stock after buying an additional 750 shares during the quarter. Nisa Investment Advisors LLC’s holdings in AstraZeneca were worth $103,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Axxcess Wealth Management LLC grew its holdings in AstraZeneca by 6.0% during the first quarter. Axxcess Wealth Management LLC now owns 21,615 shares of the company’s stock valued at $1,589,000 after purchasing an additional 1,221 shares during the period. Rehmann Capital Advisory Group boosted its position in shares of AstraZeneca by 5.3% during the first quarter. Rehmann Capital Advisory Group now owns 11,290 shares of the company’s stock worth $830,000 after purchasing an additional 570 shares in the last quarter. Cornerstone Planning Group LLC grew its holdings in shares of AstraZeneca by 392.9% in the 1st quarter. Cornerstone Planning Group LLC now owns 695 shares of the company’s stock valued at $48,000 after buying an additional 554 shares during the period. Principal Securities Inc. increased its position in shares of AstraZeneca by 0.5% in the 1st quarter. Principal Securities Inc. now owns 28,053 shares of the company’s stock valued at $2,062,000 after buying an additional 142 shares in the last quarter. Finally, Trium Capital LLP acquired a new stake in AstraZeneca during the 1st quarter worth $7,544,000. Institutional investors and hedge funds own 20.35% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on AZN. Berenberg Bank set a $97.00 target price on AstraZeneca in a research note on Wednesday, July 9th. BNP Paribas initiated coverage on AstraZeneca in a research report on Tuesday, April 15th. They issued an “outperform” rating and a $75.00 price objective for the company. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, AstraZeneca currently has an average rating of “Moderate Buy” and an average price target of $89.00.

AstraZeneca Stock Performance

AZN opened at $68.79 on Friday. The company has a market capitalization of $213.34 billion, a price-to-earnings ratio of 27.63, a P/E/G ratio of 1.27 and a beta of 0.37. The business’s 50-day moving average price is $70.78 and its two-hundred day moving average price is $70.92. AstraZeneca PLC has a 1 year low of $61.24 and a 1 year high of $87.68. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.90 and a quick ratio of 0.70.

AstraZeneca (NASDAQ:AZN) last announced its earnings results on Tuesday, April 29th. The company reported $1.24 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.10 by $0.14. AstraZeneca had a return on equity of 33.14% and a net margin of 14.14%. The business had revenue of $13.59 billion for the quarter, compared to analyst estimates of $13.71 billion. During the same quarter last year, the firm earned $2.06 EPS. AstraZeneca’s revenue for the quarter was up 7.2% compared to the same quarter last year. Equities analysts expect that AstraZeneca PLC will post 4.51 EPS for the current fiscal year.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.